BRAF Targets in Melanoma (eBook)
VIII, 204 Seiten
Springer New York (Verlag)
978-1-4939-2143-0 (ISBN)
Dr. Ryan J. Sullivan is affiliated with Massachusetts General Hospital and Dana Farber. His research interests are in the development of novel molecular therapeutic agents for Kaposi sarcoma (KS) and malignant melanoma and the translation of promising preclinical findings into early stage clinical trials. He serves as the co-director of the Eugene Michael Egan Melanoma Translational Research Laboratory at Beth Israel Deaconess Medical Center (BIDMC) and is actively investigating promising biomarkers of response and benefit to immunotherapy and molecular targeted therapy for patients with melanoma.
?This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.
Dr. Ryan J. Sullivan is affiliated with Massachusetts General Hospital and Dana Farber. His research interests are in the development of novel molecular therapeutic agents for Kaposi sarcoma (KS) and malignant melanoma and the translation of promising preclinical findings into early stage clinical trials. He serves as the co-director of the Eugene Michael Egan Melanoma Translational Research Laboratory at Beth Israel Deaconess Medical Center (BIDMC) and is actively investigating promising biomarkers of response and benefit to immunotherapy and molecular targeted therapy for patients with melanoma.
1. Melanoma: Historical ContextSuraj Venna, Sekwon Jang, Michael Atkins2. Melanoma PathogenesisJennifer A. Lo, David E. Fisher3. Molecular Diagnostics and Tumor Mutational AnalysisMelissa A. Wilson and Katherine L. Nathanson4. Clinical Utility of BRAF-targeted therapy in MelanomaJeffrey A. Sosman and Douglas B. Johnson5. The Ethics of Randomized Trials in OncologyPallavi Kumar, Ryan J. Sullivan6. Parallel and Serial Blockade Strategies in BRAF-Mutant MelanomaMichael A. Davies7. Targeting the cell cycle and p53 in combination with BRAF-directed therapyDale Han, Keiran SM Smalley8. Combination BRAF-directed therapy and immunotherapyZachary A. Cooper, Zain Ahmed, Jennifer A. Wargo9. Moving Forward: Making BRAF-Targeted Therapy BetterKeith T Flaherty
| Erscheint lt. Verlag | 24.11.2014 |
|---|---|
| Reihe/Serie | Cancer Drug Discovery and Development | Cancer Drug Discovery and Development |
| Zusatzinfo | VIII, 204 p. 26 illus., 21 illus. in color. |
| Verlagsort | New York |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Dermatologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Studium | |
| Naturwissenschaften ► Biologie | |
| Technik | |
| Schlagworte | BRAF-inhibitors • immunotherapy • Next-Gen Sequencing • p53 • vemurafenib |
| ISBN-10 | 1-4939-2143-6 / 1493921436 |
| ISBN-13 | 978-1-4939-2143-0 / 9781493921430 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 4,8 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
